For the quarter ending 2026-02-28.
| Income Statement | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|---|
| Services | 0 | 0 | 0* | 0 |
| Cost of services | 0 | - | - | - |
| Gross profit | 0 | - | - | - |
| Research and development expense | 0 | - | 0* | 0 |
| General and administrative expenses | 72,963 | 64,002 | 162,286.25* | 40,380 |
| Total operating expenses | 72,963 | 64,002 | 162,286.25* | 40,380 |
| Loss from operations | -72,963 | -64,002 | -162,286.25* | -40,380 |
| Capital loss | 0 | - | - | - |
| Financial income (loss), net | 28,865 | -49,717 | - | -19,347 |
| Capital loss | - | - | 0* | - |
| Capital gain (loss) | - | - | - | 0 |
| Financial loss, net | - | - | 10,571.25* | - |
| Net (loss) | -44,098 | -113,719 | -172,857.5 | -59,727 |
| Profit (loss) from available for sale assets | 0 | 0 | - | 0 |
| Total comprehensive income (loss) | -44,098 | -113,719 | -172,857.5 | -59,727 |
| Basic EPS | 0 | 0 | -0.001 | 0 |
| Diluted EPS | 0 | 0 | -0.001 | 0 |
| Basic Average Shares | 931,015,714 | 732,857,211 | 198,239,676 | 42,597,394 |
| Diluted Average Shares | 931,015,714 | 732,857,211 | 198,239,676 | 42,597,394 |
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)